Washington University Initiates Clinical Study of Verastem's VS-6063 in Combination with Merck's Pembrolizumab and Gemcitabine in Pancreatic Cancer

Verastem, Inc.

today announced the initiation of a Phase 1 dose-escalation study at Washington University to evaluate Verastem's FAK inhibitor VS-6063 in combination with Merck's PD-1 inhibitor pembrolizumab and gemcitabine in patients with pancreatic cancer. This is the first of several combination clinical trials the Company expects to initiate this year. This Phase 1 clinical trial is anticipated to enroll approximately 50 patients and is being conducted at the Washington University School of Medicine's Division of Oncology under the direction of Andrea Wang-Gillam, MD, PhD, Clinical Director of the Gastrointestinal Oncology Program.